Abstract

The present invention relates to a device for filtering fluid samples and a method for detecting concentration of particles, and more particularly to a filtering device capable of filtering fluid samples at different filtering levels and a method for detecting the concentration of particles trapped in the filters of the device for each fluid sample.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01D 63/08 - Flat membrane modules

Abstract

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens

Abstract

The present invention provides anti-Siglec-15 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-15 antibodies and fragments thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors

Abstract

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating a ketone (—C═O) or an oxime group (—C═N—O—) as position C3 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61K 39/095 - Neisseria
• A61K 39/13 - Poliovirus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents
• C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Abstract

The present invention relates to a novel RNA-guided Cas nuclease having the sequence shown in SEQ. ID. No.1 and designated α-synCs. It shares low sequence homology with known Cas nucleases and has the following advantageous properties: (i) ability to target for nucleolytic cleavage all of dsDNA, ssDNA and ssRNA (ii) able to non-sequence-specifically trans-cleave all of dsDNA, ssDNA and ssRNA regardless of which target it has been activated by (ii) appears to have no PAM specificity (iii) ability to use a wide range of crRNAs belonging to a plurality of Cas nucleases for targeted cleavage and (iv) ability to process pre-crRNA transcripts.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• A61K 38/46 - Hydrolases (3)
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating an oxime group at position C4 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

IPC Classes  ?

• C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• C07K 14/445 - Plasmodium
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The invention relates to an agent binding specifically to the sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 wherein said agent is an immunoglobulin agent or a non-immunoglobulin agent selected from the group consisting of a peptide aptamer, a nucleic acid aptamer, a DARPin, an affibody, and an anticalin. The invention also relates to a nucleic acid, an expression cassette, a vector, a cell and a nanoparticle comprising the agent of the invention. The invention also relates to a pharmaceutical composition and to its use in preventing and/or treating cancer, metastasis or fibrosis. The invention also relates to a method for screening compounds capable of inhibiting Wnt-11.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/475 - Growth factorsGrowth regulators

Abstract

The present invention relates to an oral composition of ciclopirox or a derivate thereof which do not exhibit gastrointestinal toxicity and comprises a therapeutically effective amount of ciclopirox, tocopherol and alginate or their derivates.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The present invention relates to methods for the purification by affinity binding of SUMO (Small-ubiquitin modifier) and SUMO-conjugate proteins by the use of fusion proteins comprising tandem arrangements of high affinity SUMO interacting motifs.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

The present application relates to compounds based on a triterpene glycoside saponin scaffold, which bear an acyl chain comprising a photoreactive moiety and a terminal biotin, of general formula (I). The present application also relates to the use of said compounds and compositions thereof in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers as well as its use as chemical probe in photoaffinity labeling (PAL) (for photocrosslinking with interacting partners) followed by affinity purification of the covalent complex and MS-based proteomics for target identification and elucidation of the protein receptor.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07H 1/08 - SeparationPurification from natural products
• C07H 15/256 - Polyterpene radicals
• C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms

Abstract

The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to the use of uroporphyrin I (UROI) or a pharmaceutically acceptable salt or metallo-complex thereof for the treatment and/or prevention of transmissible spongiform encephalopathies (TSE) or prion diseases.

IPC Classes  ?

• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to a method for diagnosing liver disease in a subject and/or for triaging a subject for liver disease, which is based on the detection of the expression level of GNMT in a urine sample from said subject. The invention also relates to methods for monitoring progression of liver disease, for monitoring a patient's response to a therapy for liver disease, and for selecting a subject to be treated for liver disease. The invention also describes the use of reagents specific for determining the expression level of GNMT in a urine sample from a subject, for in vitro diagnosing a liver disease in said subject.

IPC Classes  ?

• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Enzymes for industrial purposes; Enzymes for scientific purposes; Enzyme preparations for industrial purposes; Enzyme preparations for scientific purposes; Enzymes for genome editing for scientific and research purposes; Enzymes preparations for genome editing for scientific and research purposes; Diagnostic preparations, other than for medical or veterinary purposes; Reagents for scientific purposes; Reagents for research purposes; Reagents for genome editing for scientific and research purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr controls being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr reagents for genome editing for scientific and research purposes; Chemical substances for use in the biotechnological industry; Chemical reagents for use in biotechnology, other than for medical or veterinary use; Chemical preparations for use in DNA analysis, other than medical use; Enzyme preparations for use in DNA analysis, other than medical use; Enzymes for use in DNA analysis, other than medical use; Chemical preparations for use in RNA analysis, other than medical use; Enzyme preparations for use in RNA analysis, other than medical use; Enzymes for use in RNA analysis, other than medical use; Enzymes for editing genomes for medical or veterinary research purposes Enzymes for medical purposes; Enzymes for veterinary purposes; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Enzyme preparations for editing genomes for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for genome editing for medical or veterinary purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr controls being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr reagents for genome editing for medical or veterinary purposes; Chemical preparations for use in DNA analysis for medical or veterinary purposes; Enzyme preparations for use in DNA analysis for medical or veterinary purposes; Enzymes for use in DNA analysis for medical or veterinary purposes; Chemical preparations for use in RNA analysis for medical or veterinary purposes; Enzyme preparations for use in RNA analysis for medical or veterinary purposes; Enzymes for use in RNA analysis for medical or veterinary purposes Research in the field of gene therapy; Advisory services relating to gene therapy research; Research in the field of gene editing technology; Advisory services in the field of gene editing technology; Genome editing for scientific purposes; Genome editing for scientific research purposes; Genome editing for industrial purposes; Genome editing for use in biotechnology, other than for medical or veterinary use Genome editing for medical purposes; Genome editing for veterinary purposes

Abstract

T. thermosaccharolyticumThermomyces lanuginosus,Thermomyces lanuginosus, obtaining a novel acylated derivate of phloretin, particularly the phloretin 4'-O-(6-O- lauroyl)-α-D-glucopyranoside. Further, the present invention relates the use of phloretin 4'-O-(6-O-lauroyl)-α-D-glucopyranoside as antioxidant.

IPC Classes  ?

• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
• A61P 17/18 - Antioxidants, e.g. antiradicals
• C12P 7/6454 - Glycerides by esterification
• C12P 19/02 - Monosaccharides

Goods & Services

Enzymes for industrial purposes; Enzymes for scientific purposes; Enzyme preparations for industrial purposes; Enzyme preparations for scientific purposes; Enzymes for genome editing for scientific and research purposes; Enzymes preparations for genome editing for scientific and research purposes; Diagnostic preparations, other than for medical or veterinary purposes; Reagents for scientific purposes; Reagents for research purposes; Reagents for genome editing for scientific and research purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr controls being biochemical, chemical, and biological preparations for scientific and research purposes; Crispr reagents for genome editing for scientific and research purposes; Chemical substances for use in the biotechnological industry; Chemical reagents for use in biotechnology, other than for medical or veterinary use; Chemical preparations for use in DNA analysis [other than medical]; Enzyme preparations for use in DNA analysis [other than medical]; Enzymes for use in DNA analysis [other than medical]; Chemical preparations for use in RNA analysis [other than medical]; Enzyme preparations for use in RNA analysis [other than medical]; Enzymes for use in RNA analysis [other than medical]. Enzymes for medical purposes; Enzymes for veterinary purposes; Enzyme preparations for medical purposes; Enzyme preparations for veterinary purposes; Enzymes for editing genomes for medical or veterinary research purposes; Enzyme preparations for editing genomes for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for veterinary purposes; Reagents for use in medical genetic testing; Reagents for use in veterinary genetic testing; Reagents for genome editing for medical or veterinary purposes; Crispr inhibitors being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr controls being biochemical, chemical, and biological preparations for medical or veterinary purposes; Crispr reagents for genome editing for medical or veterinary purposes; Chemical preparations for use in DNA analysis for medical or veterinary purposes; Enzyme preparations for use in DNA analysis for medical or veterinary purposes; Enzymes for use in DNA analysis for medical or veterinary purposes; Chemical preparations for use in RNA analysis for medical or veterinary purposes; Enzyme preparations for use in RNA analysis for medical or veterinary purposes; Enzymes for use in RNA analysis for medical or veterinary purposes. Research in the field of gene therapy; Advisory services relating to gene therapy research; Research in the field of gene editing technology; Advisory services in the field of gene editing technology; Genome editing for scientific purposes; Genome editing for scientific research purposes; Genome editing for industrial purposes; Genome editing for use in biotechnology, other than for medical or veterinary use. Genome editing for medical purposes; Genome editing for veterinary purposes.

Abstract

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating a ketone (-C=O) or an oxime group (-C=N-O-) as position C3 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

IPC Classes  ?

• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C07K 14/445 - Plasmodium
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 47/02 - Inorganic compounds
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an oral composition of ciclopirox or a derivate thereof which do not exhibit gastrointestinal toxicity and comprises a therapeutically effective amount of ciclopirox, tocopherol and alginate or their derivates.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating an oxime group at position C4 of the triterpene domain and pharmaceutical compositions thereof as well as the use of said compounds and compositions in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07H 15/256 - Polyterpene radicals
• C07J 63/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/22 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Neisseriaceae (F), e.g. Acinetobacter
• C07K 14/445 - Plasmodium
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a method for expanding a population of T-lymphocytes, to the population of expanded T-lymphocytes obtained by this method and to the medical use of this population of expanded T-lymphocytes for the treatment of cancer or of an infectious disease.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to a method for diagnosing inflammation in a subject based on determining the level of expression of IRF4 in sample from said subject and to a method for designing a personalized therapy in a subject suffering from inflammation. The invention also relates to a combination comprising a compound suitable for treating inflammation and a compound selected from the group consisting of a glycolysis inhibitor, an IRF4 mimetic, a Ras inhibitor, a PI-3K inhibitor, a mTOR inhibitor, a STAT3 inhibitor, an antioxidant and combinations thereof and to medical uses for preventing and/or treating inflammation. The invention also relates to the use of a kit comprising a reagent suitable for determining the level of expression of IRF4 in a sample for diagnosing inflammation in a subject.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The present invention relates to a CNNM4 inhibitor for use in the treatment of an acute or a chronic liver, kidney and/or lung disease in a subject, and to pharmaceutical compositions comprising a therapeutically effective amount of a CNNM4 inhibitor and a pharmaceutically acceptable excipient or carrier. Furthermore, the invention relates to a method for diagnosing a liver disease, a kidney disease or a lung disease in a subject, and to in vitro methods for identifying a compound potentially useful for reducing an induced CNNM4-mediated disease or condition in a cell.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61P 3/06 - Antihyperlipidemics
• A61P 3/12 - Drugs for disorders of the metabolism for electrolyte homeostasis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention relates to new methods for predicting the outcome of in vitro fertilization (IVF) procedures, as well as selecting the subjects to undergo IVF treatments. It also relates to methods for selecting IVF treatments and decision-making in said treatments as well as wash solutions for use in the treatment of infertility.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The present invention relates to methods useful for predicting the outcome of a patient suffering from prostate cancer or for predicting the response to therapy of a patient suffering from prostate cancer, which comprise determining, in a sample from the patient, the ratio between the average expression levels of a first gene signature and the average expression levels of a second gene signature, wherein the first gene signature is selected from the group consisting of HI1 (i.e., the CPOX, GAL3St4, ORAI2 and NIPA1 genes) and HI2 (i.e., the KHK, NOX4, PTGES3 and RRM2 genes); wherein the second gene signature is selected from the group consisting of LO1 (i.e., the ATP8B1, CDO1, CHRNA2, GLB1L3, GNE, KATNAL2, PTGIS, SLC6A14, TP53INP2, and TRIM47 genes), LO2 (i.e., the ASPA, CDO1, CYP3A5, GLB1L2, GNE, ITPKC, KCTD14, PAH, PHYHD1, SIRT1, SLC40A1, SLC7A4, and SRD5A genes) and LO3 (i.e., the ASPA, CDO1, GFPT2, GNE, ITPKC, PAH, SIRT1 and TPMT genes). These methods can be used to identify those patients who harbour an indolent/ low risk prostate cancer, or those that are at a high risk of recurrence or metastasis. The identification of these subgroups of patients may guide the selection of therapies, improving financial and health outcomes. Moreover, the expression levels of these genes can also be used for the selection of a patient to be treated for low risk, indolent, localised, advanced, recurrent or metastatic prostate cancer. Further, the invention also relates to kits and reagents to determine the expression levels of these genes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention is directed to a device for containing and placing ticks or other small sized animals on laboratory animals in order to perform controlled feeding experiments and a method of use thereof; in particular the present invention proposes a capsule (10) that is compact in size and easily accessible to permit feeding of small sized animals such as ticks on laboratory and larger animals.

IPC Classes  ?

• A01K 1/03 - Housing for domestic or laboratory animals
• A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates

Abstract

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.

IPC Classes  ?

• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor

Abstract

The present invention relates to a CNNM4 inhibitor for use in the treatment of an acute or a chronic liver, kidney and/or lung disease in a subject, and to pharmaceutical compositions comprising a therapeutically effective amount of a CNNM4 inhibitor and a pharmaceutically acceptable excipient or carrier. Furthermore, the invention relates to a method for diagnosing a liver disease, a kidney disease or a lung disease in a subject, and to in vitro methods for identifying a compound potentially useful for reducing an induced CNNM4-mediated disease or condition in a cell.

IPC Classes  ?

• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings

Goods & Services

Computer software; Electronic publications, downloadable; all the aforementioned related to biosciences. Printed publications; Printed matter; Books; Magazines [periodicals]; Instructional and teaching material (except apparatus); Stationery; all the aforementioned related to biosciences. Education; Providing of training; Organisation of conferences, exhibitions and competitions; Audio, video and multimedia production, and photography; Library services; Publishing and reporting; all the aforementioned related to biosciences. Science and technology services; Research relating to technology; Scientific services and design relating thereto; Technological services and design relating thereto; Scientific research; Biological research; Biological analysis; Biology consultancy; Medical and pharmacological research services; Biological big data analytics; Software design and development; Design and development of computer hardware; Testing, authentication and quality control; Scientific testing services; Software as a service [SaaS]; Providing temporary use of non-downloadable software applications accessible via a web site; all the aforementioned related to biosciences. Medical testing for diagnostic or treatment purposes; Drug screening for medical purposes; Performing diagnosis of diseases; all the aforementioned related to biosciences.

Goods & Services

Computer software; Electronic publications, downloadable. Education; Providing of training; Organisation of conferences, exhibitions and competitions; Audio, video and multimedia production, and photography; Library services; Publishing and reporting. Science and technology services; Research relating to technology; Scientific services and design relating thereto; Technological services and design relating thereto; Scientific research; Biological research; Biological analysis; Biology consultancy; Medical and pharmacological research services; Biological big data analytics; Software design and development; Design and development of computer hardware; Testing, authentication and quality control; Scientific testing services; Software as a service [SaaS]; Providing temporary use of non-downloadable software applications accessible via a web site. Medical services; Medical treatment services; Medical testing for diagnostic or treatment purposes; Preparation of prescriptions by pharmacists; Drug screening for medical purposes; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Performing diagnosis of diseases.

Abstract

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of congenital erythropoietic porphyria (CEP).

IPC Classes  ?

• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

Methods and compounds useful to treat drug-induced diseases and conditions are provided. Methods of administering one or more MCJ-inhibiting compounds to decrease MCJ polypeptide activity in cells, tissues, and/or subjects as a treatment for a drug-induced disease or condition are provided.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of a disease caused by dysregulated heme group biosynthesis, with the proviso that said disease is not congenital erythropoietic porphyria.

IPC Classes  ?

• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to biomarkers for colorectal cancer. Specifically, it relates to metabolic markers as a screening, diagnostic or monitoring tool for detecting colorectal cancer (CRC) and /or advanced adenoma (AD) in a subject. In a particular embodiment, it refers to an in vitro method for the screening, diagnosis or monitoring of colorectal cancer and /or advanced adenoma in a subject, said method comprising the following steps: a) determining the levels of the metabolic marker ChoE(18:2) in a feces sample isolated from said subject; b) comparing the levels in said feces sample with a reference value; wherein an increase of ChoE(18:2) levels in the subject sample with regard to said reference value is indicative of CRCand /or AD.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

Methods and compounds useful to treat diseases and conditions are provided. Methods of administering one or more microRNA-inhibitor compounds or one or more microRNA-enhancing compounds to cells, tissues, and/or subjects as a treatment for a disease or condition are provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a set of markers, preferably proteins, all associated with the path of the system for activating the complement, which are particularly useful for predicting and/or forecasting the compatibility in vitro of a biomaterial, for example such as prosthetic joints, dental prostheses, valves, stents, etc. in the patient. In addition, the present invention comprises an in vitro method for predicting and/or forecasting the compatibility of said materials by determining the peptide profile described in the invention, as well as a kit and/or a device for carrying out said method.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to the use of the compound ciclopirox or a pharmaceutically acceptable salt or solvate thereof for the treatment and/or prevention of congenital erythropoietic porphyria (CEP).

IPC Classes  ?

• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to methods useful for predicting the outcome of a patient suffering from prostate cancer or for predicting the response to therapy of a patient suffering from prostate cancer, which comprise the determination of the expression level of PGC1A or of a gene signature under the control of PGC1A. These methods can be used to identify those patients who are at a high risk of recurrence or metastasis. The identification of this subgroup of patients may guide the selection of therapies, improving financial and health outcomes. Moreover, the expression levels of these genes can also be used for the selection of a patient to be treated for advanced, recurrent or metastatic prostate cancer. Further, the invention also relates to kits and reagents to determine the expression levels of these genes.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Methods and compounds useful to treat diseases and conditions are provided. Methods of administering one or more microRNA-inhibitor compounds or one or more microRNA-enhancing compounds to cells, tissues, and/or subjects as a treatment for a disease or condition are provided.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose

Abstract

Methods and compounds useful to treat drug-induced diseases and conditions are provided. Methods of administering one or more MCJ-inhibiting compounds to decrease MCJ polypeptide activity in cells, tissues, and/or subjects as a treatment for a drug-induced disease or condition are provided.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The potential use of these “SUMO receptors” to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

4 represents (II) or (III) in the preparation of a medicinal product for treating and/or preventing congenital erythropoietic porphyria (CEP).

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin

Abstract

The potential use of these "SUMO receptors" to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The invention relates to methods for the diagnosis of liver damage. The method relies on the determination of certain metabolic markers in a biological sample of the subject which are up- or down-regulated in injured liver.

IPC Classes  ?

• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

A device for storing a plurality of cryo-grid storage boxes in a dewar, comprising a substantially cylindrical body having a diameter, wherein said diameter is such that the device fits substantially exactly in a dewar canister, and said cylindrical body comprises a plurality of storage holes, the cross-sectional dimensions of the storage holes being adapted to a standard-size cryo-grid storage box such that each storage hole fits at least one standard-size cryo-grid storage box.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• B01L 9/06 - Test-tube standsTest-tube holders
• F25D 25/00 - Charging, supporting, or discharging the articles to be cooled
• A61N 1/02 - ElectrotherapyCircuits therefor Details